News

Multiconsult ASA's Third Quarter Insights: Trends and Growth

Multiconsult ASA's Third Quarter Insights: Trends and Growth

Multiconsult ASA Reports Third Quarter Performance

OSLO, Norway - Multiconsult ASA (OSE: MULTI) recently reported its performance for the third quarter. The company showed a stable performance despite facing a competitive market, rising costs, and other industry challenges. Net operating revenues saw an increase of 4.2 percent, reaching NOK 1,196.4 million, with an adjusted organic revenue growth of 6.7 percent. The EBITA adjusted was NOK 62.1 million with a margin of 5.2 percent.

Financial Highlights

For the latest quarter, EBITA stood at NOK 62.1 million, translating to a year-to-date EBITA of NOK 319.9 million. The EBITA margin was calculated at 5.2 percent for this quarter and 7.7 percent year-to-date. It is essential to note that during the same quarter in the previous year, a one-off settlement payment of NOK 31.2 million negatively impacted performance compared to this year.

Current Market Conditions

While the overall activity level across most segments remained high, certain uncertainties in the market have emerged. Delays in starting large framework agreements have created some challenges, resulting in slightly increased margin pressure. The billing ratio was noted at 70.1 percent, dipping by 1.1 percentage points year-over-year. Despite these challenges, order intake reached NOK 1,205 million, leading to an impressive order backlog of NOK 4,316 million.

The Future Ahead

An important highlight from the third quarter includes the signing of the share purchase agreement for acquiring the ViaNova group, with the closing scheduled for mid-November. Company leadership emphasizes that stabilizing the company's performance is crucial, especially with the fluctuating market conditions.

Year-to-Date Performance Overview

Looking at year-to-date statistics for 2025, Multiconsult has reported net operating revenues of NOK 4,135.7 million, noting a year-over-year growth of 5 percent. The EBITA adjusted number for the year stands at NOK 319.9 million, reflecting an EBITA margin of 7.7 percent.

Insights from the CEO

Grethe Bergly, CEO of Multiconsult, reflected on the company's achievements and the path ahead. She stated, "In the third quarter, we delivered strong organic growth, emphasizing that demand for our services remains robust due to new framework agreements and assignments. However, the results reflect a complex situation that needs addressing, especially to enhance the billing ratio, manage costs effectively, and regain momentum. I am determined to guide the company back on its successful path since 2020."

Expert Staff and Strategic Initiatives

Multiconsult's team of highly skilled professionals, exceeding 4,000, remains dedicated to not only meeting but anticipating future demands across various sectors. The company is focusing on sales and project execution to harness opportunities that align with existing high demand.

Upcoming Presentations and Communiqués

The company invites stakeholders to a presentation regarding the third quarter results, held today in Oslo at the Hotel Continental. Specific sessions will be broadcast on the web, providing an opportunity for participants to submit questions during the sessions.

Frequently Asked Questions

What are the latest highlights from Multiconsult's financial performance?

Multiconsult reported a 4.2 percent increase in net operating revenues in the third quarter, amounting to NOK 1,196.4 million with EBITA at NOK 62.1 million.

Are there any expected changes in market conditions?

The company acknowledges increased uncertainties in the market which may affect future performance, especially concerning larger framework agreements.

What strategic measures is Multiconsult taking?

Multiconsult is implementing initiatives to improve its billing ratio, manage costs, and enhance project execution, aiming to regain its competitive edge.

How many employees does Multiconsult currently have?

The company employs over 4,000 skilled professionals, which is crucial for driving its strategic goals and meeting client expectations.

What is the company's outlook for the rest of the year?

While the overall market outlook seems stable, Multiconsult is preparing for potential challenges in achieving desired growth, ensuring it remains proactive in its strategies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

NanoXplore Gains Government Support for Innovative Battery Tech

Updated Category News Views 193

NanoXplore Secures Government Funding for Battery Innovation In a significant development for the battery technology sector, NanoXplore Inc. (TSX: GRA and OTCQX: NNXPF), a frontrunner in graphene production, recently announced a contribution of up to $2.75 million from the Canadian government as part of the Energy Innovation Program (EIP). This contribution is expected to...

Continue Reading
Equinor ASA Declares Cash Dividend for First Quarter 2025

Updated Category News Views 272

Equinor ASA Announces an Exciting Cash Dividend Equinor ASA (OSE: EQNR, NYSE: EQNR) has made an important announcement regarding its dividend strategy for shareholders. As part of its ongoing commitment to deliver value, the company has declared a cash dividend of NOK 3.7740 per share for the first quarter of 2025. Understanding the Dividend Amount The cash dividend of...

Continue Reading
RIAS A/S Shares Insights from Recent Half-Year Performance

Updated Category News Views 469

Analyzing the Half-Year Performance of RIAS A/S RIAS A/S has recently released its half-year report, offering a clear view into the company's operational status and financial health. This report is crucial for stakeholders and potential investors to understand how RIAS A/S is navigating through the current economic landscape. Key Financial Highlights In this reporting...

Continue Reading
Starbucks Stock Analysis: Opportunities and Challenges Ahead

Updated Category News Views 156

Understanding Starbucks Stock Performance Starbucks Corporation's stock, trading under the ticker SBUX, is currently observed at a forward 12-month Price/Earnings ratio of 24.79x. This figure places it just slightly below the Zacks Restaurant industry average of 24.97x. However, it's noteworthy that SBUX's valuation exceeds the broader Retail-Wholesale sector, which has a...

Continue Reading
Explore Innovations at the 2024 GenScript Biotech Forum

Updated Category News Views 314

Join Experts at the 2024 GenScript Biotech Global Forum The year ahead is shaping up to be crucial for Cell and Gene Therapy (CGT), and the "2024 GenScript Biotech Global Forum" offers an ideal setting for essential discussions. Top experts will gather to exchange insights on groundbreaking therapies such as Amtagvi and PM359, which promise new opportunities in treatment....

Continue Reading